SURGIFOAM Absorbable Gelatin Sponge
Ferrosan Meidcal Devices A/S · Decision date Jun 17, 2026
What did the FDA decide?
FDA records P990004/S081 as a supplement to PMA P990004, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 17, 2026.
FDA approval order statement
Change in location of process step from one cleanroom to a different cleanroom at the same site
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Jun 17, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P990004/S081
- Regulatory pathway
- PMA supplement
- Applicant
- Ferrosan Meidcal Devices A/S
- Product code
- LMF
- Decision code
- OK30
- Decision date
- Jun 17, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, collagen based.
- Applicant
- Ferrosan Meidcal Devices A/S
- Product code
- LMF
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P990004. Subsequent supplements may change the device or its indications.
FDA decision timeline
P990004 · Original PMA
SURGIFOAM ABSORBABLE GELATIN SPONGE, USP
P990004/S075 · Related supplement
SURGIFLO Hemostatic Matrix; SURGIFLO Hemostatic Matrix Kit with Thrombin
P990004/S076 · Related supplement
SURGIFOAM Absorbable Gelatin Sponge
P990004/S077 · Related supplement
SURGIFOAM Absorbable Gelatin Sponge, USP
P990004/S078 · Related supplement
SURGIFOAM Absorbable Gelatin Sponge
P990004/S079 · Related supplement
SURGIFOAM Absorbable Gelatin Sponge
P990004/S081 received
Application receipt date recorded by FDA.
P990004/S081 · FDA decision
30-Day Notice
P990004/S080 · Related supplement
SURGIFOAM Absorbable Gelatin Sponge
Timeline entries are records held by MedtechLedger for P990004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P990004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Ferrosan Meidcal Devices A/S | PMA approval | Sep 30, 1999 | FDA | |
| Ferrosan Meidcal Devices A/S | PMA supplement | Jul 18, 2025 | FDA | |
SURGIFOAM Absorbable Gelatin SpongeP990004/S076 | Ferrosan Meidcal Devices A/S | PMA supplement | Sep 8, 2025 | FDA |
SURGIFOAM Absorbable Gelatin Sponge, USPP990004/S077 | Ferrosan Meidcal Devices A/S | PMA supplement | Jan 28, 2026 | FDA |
SURGIFOAM Absorbable Gelatin SpongeP990004/S078 | Ferrosan Meidcal Devices A/S | PMA supplement | Feb 11, 2026 | FDA |
SURGIFOAM Absorbable Gelatin SpongeP990004/S079 | Ferrosan Meidcal Devices A/S | PMA supplement | Mar 24, 2026 | FDA |
SURGIFOAM Absorbable Gelatin SpongeP990004/S080 | Ferrosan Meidcal Devices A/S | PMA supplement | Sep 18, 2026 | FDA |
Explore the linked device profile
Other records with product code LMF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| C.R. Bard, Inc. | PMA supplement | Sep 29, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
| Davol Inc., Sub. C. R. Bard, Inc. | PMA supplement | Jul 15, 2026 | FDA | |
| C.R. Bard, Inc. | PMA supplement | Jul 15, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ferrosan Meidcal Devices A/S
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Sydmarken 5, Soeborg, 08876
Sources and methodology
- Original FDA record: P990004/S081
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

